Early response of bone metastases can predict tumor response in patients with non-small-cell lung cancer with bone metastases in the treatment with nivolumab

被引：15

作者：

Nakata, Eiji ^{[1
]}

Sugihara, Shinsuke ^{[2
]}

Sugawara, Yoshifumi ^{[3
]}

Kozuki, Toshiyuki ^{[4
]}

Harada, Daijiro ^{[4
]}

Nogami, Naoyuki ^{[4
]}

Nakahara, Ryuichi ^{[1
]}

Furumatsu, Takayuki ^{[1
]}

Tetsunaga, Tomonori ^{[1
]}

Kunisada, Toshiyuki ^{[1
]}

Ozaki, Toshifumi ^{[1
]}

机构：

[1] Okayama Univ Hosp, Dept Orthoped Surg, 2-5-1 Shikata Cho, Okayama 7008558, Japan

[2] Shikoku Canc Ctr, Dept Orthoped Surg, Matsuyama, Ehime 7910280, Japan

[3] Shikoku Canc Ctr, Dept Radiol, Matsuyama, Ehime 7910280, Japan

[4] Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime 7910280, Japan

来源：

ONCOLOGY LETTERS | 2020年 / 20卷 / 03期

关键词：

bone metastasis; non-small-cell lung cancer; programmed cell death 1; nivolumab; Response Evaluation Criteria in Solid Tumors; version; 1; MD Anderson response criteria; CRITERIA; INHIBITORS; DOCETAXEL; SAFETY;

D O I：

10.3892/ol.2020.11856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The effect of nivolumab and the relation between bone response and tumor control in patients with non-small-cell lung cancer (NSCLC) with bone metastases are not clear. The outcome of nivolumab monotherapy was investigated, and whether the response of bone metastases is useful as an early predictor of tumor control in patients with NSCLC with bone metastases was examined. The participants included 15 patients who received nivolumab monotherapy for NSCLC with bone metastases in our institution between 2015 and 2017. Tumor control was defined using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST1.1). Response of bone metastases was assessed by the MD Anderson response criteria (MDA criteria). Responses according to RECIST1.1 and the MDA criteria were classified as responder (complete response or partial response) and non-responder [progressive disease (PD) or stable disease]. Progression-free survival (PFS) was investigated using the Kaplan-Meier method. With RECIST1.1, the overall response rate was 20%. Multivariate analysis showed that the MDA criteria were the only risk factor for patients with PD (RECIST1.1). Median PFS was 1.9 months, with PFS of 20% at 6 months. Univariate analysis showed that being a non-responder according to the MDA criteria was the only risk factor for PFS. In patients who were responders (MDA criteria) within 3 months, PFS was 83 and 50% at 3 and 6 months, respectively, though all non-responder (MDA criteria) patients converted to PD (RECIST1.1) within 3 months. Response according to RECIST1.1 was significantly correlated with response according to the MDA criteria (P<0.05). In patients who were both responders according to RECIST1.1 and the MDA criteria, time to response with the MDA criteria (1.4-2.0 months) was earlier than with RECIST1.1 (2.8-3.0 months) in all patients. In conclusion, application of the MDA criteria within 2 months of nivolumab monotherapy is useful for early prediction of response and prognosis in patients with NSCLC with bone metastases.

引用

页码：2977 / 2986

页数：10

共 28 条

[1] Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases [J].

Amir, E. ;

Whyne, C. ;

Freedman, O. C. ;

Fralick, M. ;

Kumar, R. ;

Hardisty, M. ;

Clemons, M. .

CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (05) :479-484

[2] Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update [J].

Blons, Helene ;

Garinet, Simon ;

Laurent-Puig, Pierre ;

Oudart, Jean-Baptiste .

JOURNAL OF THORACIC DISEASE, 2019, 11 :S25-S36

[3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[5] Bone matters in lung cancer [J].

Brodowicz, T. ;

O'Byrne, K. ;

Manegold, C. .

ANNALS OF ONCOLOGY, 2012, 23 (09) :2215-2222

[6] Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy [J].

Chang, Connie Y. ;

Simeone, F. Joseph ;

Torriani, Martin ;

Bredella, Miriam A. .

SKELETAL RADIOLOGY, 2017, 46 (10) :1385-1395

[7]

Costelloe CM, 2010, J CANCER, V1, P80

[8] Immune checkpoint inhibitors: recent progress and potential biomarkers [J].

Darvin, Pramod ;

Toor, Salman M. ;

Nair, Varun Sasidharan ;

Elkord, Eyad .

EXPERIMENTAL AND MOLECULAR MEDICINE, 2018, 50 :1-11

[9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[10] Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study [J].

Gettinger, Scott ;

Horn, Leora ;

Jackman, David ;

Spigel, David ;

Antonia, Scott ;

Hellmann, Matthew ;

Powderly, John ;

Heist, Rebecca ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Geese, William J. ;

Yoon, Dennis ;

Li, Ang ;

Brahmer, Julie .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1675-+

← 1 2 3 →